FDA relaxes cardiovascular trial requirements for diabetes drugs

被引：0
作者：
Asher Mullard [ ]
机构：
来源：
Nature Reviews Drug Discovery | 2020年 / 19卷 / 5期
关键词：
D O I：
10.1038/d41573-020-00071-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：298 / 298
相关论文
共 50 条
  • [31] DIABETES DRUGS - CLINICAL-TRIAL
    PROUT, TE
    KNATTERUD, GL
    MEINERT, CG
    SCIENCE, 1979, 204 (4391) : 362 - 363
  • [32] Diabetes drugs pass cardiovascular risk check
    Opar, Alisa
    NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (05) : 343 - U8
  • [33] Requirements for FDA Approval
    Basu, Sankar
    PROCEEDINGS OF LIGHT-ACTIVATED TISSUE REGENERATION AND THERAPY CONFERENCE, 2008, 12 : 269 - 269
  • [34] FDA is to assess data linking type 2 diabetes drugs with pancreatitis
    Cohen, Deborah
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [35] US FDA approve three new drugs for Type 2 diabetes
    Bond, Theo
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (02) : 103 - 103
  • [36] US FDA approves three new drugs for Type 2 diabetes
    Bond, Theo
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2013, 6 (02): : 101 - 101
  • [37] Post-Marketing Requirements in Diabetes Mellitus in Europe (EMA) and the USA (FDA)
    Caron, Martine
    Emery, Marie-Pierre
    Maier, Will
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 87 - 87
  • [38] Trends in FDA Postmarketing Commitments and Requirements for Newly Approved Drugs, 2011-2016
    Desai, Jayashri
    Albano, Jessica
    Sinclair, Susan
    McCormick, John P.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 353 - 354
  • [39] Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016
    Brown, Beatrice L.
    Mitra-Majumdar, Mayookha
    Darrow, Jonathan J.
    Moneer, Osman
    Pham, Catherine
    Avorn, Jerry
    Kesselheim, Aaron S.
    JAMA INTERNAL MEDICINE, 2022, 182 (11) : 1223 - 1226
  • [40] Analysing post-marketing requirements for orphan drugs approved by US FDA and EMA
    Reactions Weekly, 2024, 2024 (1) : 5 - 5
12345